Bolstering and Expanding: Kangsheng Global (09960) Wins "Best Strategic Investment Firm in Healthcare" Award

Zhitong Caijing APP has learned that on July 30, 2025, Hao Yue Capital officially released the "9th Annual Best Investment Rankings in Healthcare", and Kangsheng Global (09960) won the award for "Best Strategic Investment Firm in Healthcare" of the year, showing the company's achievements in strategic investment have gained high recognition from the capital market.

The "Best Investment Rankings in Healthcare" list, created by Hao Yue Capital, has entered its ninth year, continuously prioritizing fairness and impartiality as the evaluation criteria, comprehensively analyzing investment firms' vitality, transaction volume, return performance, and post-investment empowerment across various dimensions. This has become an important indicator for assessing the market value and brand influence of healthcare investment companies.

Since its listing, Kangsheng Global has always focused on its specialty testing business, relying on the company's deep accumulation in fields such as hematology, neurology, and solid tumors to consolidate its leading position in the industry. Through continuous R&D investments and market expansion, it has continuously expanded its business boundaries, meeting growing clinical demands.

In June 2024, Kangsheng Global acquired a 11.38% stake in Beijing Bohufu Gene Diagnostics Technology Co., Ltd., a leading company in the domestic transplantation testing and professional services field, enhancing the group's core detection technology penetration rate, influence, and customer service efficiency in the transplantation market. In September 2024, Kangsheng Global acquired 100% of Guangzhou Zhoubiao Medical Co.'s shares, rapidly entering the major solid tumor detection field, seizing the massive growth opportunities in the lung cancer, gastric cancer, and other major real entity tumor detection markets, and further expanding its pipeline for IVF products, achieving LDT and IVD dual-track development. In June 2025, Kangsheng Global established a joint venture with Biostate AI, leveraging Kangsheng Global's data and Biostate AI's artificial intelligence technology to layout key wind direction in the early screening field, driving the development of precision medicine. The above acquisition projects not only helped the company expand its business boundaries but also introduced international investors such as OrbiMed Capital, which will assist Kangsheng Global in achieving greater breakthroughs in capital markets, technology R&D, and market promotion.

Through time and space, warm currents flow. In 2025, China's healthcare industry is undergoing a structural recovery after being deep-fried. Looking at things calmly, accumulating and bursting forth. Kangsheng Global will continue to drive innovation, promoting the integration of technology and services. Meanwhile, we will actively pay attention to potential targets in the market, using valuation lows to integrate complementary technologies and companies, strengthening risk resistance and growth momentum through M&A and self-developed products and services, forming a "all-around" layout that can move forward relentlessly in the face of challenges.